Abstract
Background: Poly (ADP-ribosyl) polymerase 1 (PARP1) is important in maintaining genomic stability, repairing DNA damage, and regulating transcriptional processes. Altered PARP1 activity is associated with a multitude of pathologies especially cancer. The broad application prospects of PARP1 inhibitors attract many well-known pharmaceutical companies, which promotes the development of PARP1 inhibitors.
Objective: Present review aims to introduce PARP1 inhibitors by their structures and try to point out future development direction of PARP1 inhibitors. Method: Details regarding the PARP1and PARP1 inhibitors are obtained from PubMed literatures and patent databases. Conclusion: The action mode of PARP1 inhibitors developed so far is competing with NAD+ for the catalytic site of PARP1. Using such inhibitors affects multiple NAD+-dependent enzymatic pathways, which results in secondary toxic effects. Designing inhibitors targeting other binding sites on the PARP1 protein is a strategy to bypass this pitfall. Analyzing the structure-activity relationships of active PARP1 inhibitors described in the patents, we conclude that for the binding activity, amide group, aromatic ring or heterocyclic ring with rich electronics and heteroatom-substituted in the meta position of amide group are essential. Big substituents introduced in the heterocyclic ring can enhance inhibitory activity and improve solubility or other physicochemical properties. Clinical trials of PARP1 inhibitor were focused on cancer therapies and have achieved remarkable results.Keywords: Cancer, clinical trials, DNA repair, inhibitor, NAD+, PARP1, structure.
Recent Patents on Anti-Cancer Drug Discovery
Title:Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review
Volume: 12 Issue: 3
Author(s): Mengda Cao, Xi Sun, Yanjun Zhou, Wen Huang, Ling Meng*Ji-Fu Wei*
Affiliation:
- Research Division of Clinical Pharmacology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029,China
- First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029,China
Keywords: Cancer, clinical trials, DNA repair, inhibitor, NAD+, PARP1, structure.
Abstract: Background: Poly (ADP-ribosyl) polymerase 1 (PARP1) is important in maintaining genomic stability, repairing DNA damage, and regulating transcriptional processes. Altered PARP1 activity is associated with a multitude of pathologies especially cancer. The broad application prospects of PARP1 inhibitors attract many well-known pharmaceutical companies, which promotes the development of PARP1 inhibitors.
Objective: Present review aims to introduce PARP1 inhibitors by their structures and try to point out future development direction of PARP1 inhibitors. Method: Details regarding the PARP1and PARP1 inhibitors are obtained from PubMed literatures and patent databases. Conclusion: The action mode of PARP1 inhibitors developed so far is competing with NAD+ for the catalytic site of PARP1. Using such inhibitors affects multiple NAD+-dependent enzymatic pathways, which results in secondary toxic effects. Designing inhibitors targeting other binding sites on the PARP1 protein is a strategy to bypass this pitfall. Analyzing the structure-activity relationships of active PARP1 inhibitors described in the patents, we conclude that for the binding activity, amide group, aromatic ring or heterocyclic ring with rich electronics and heteroatom-substituted in the meta position of amide group are essential. Big substituents introduced in the heterocyclic ring can enhance inhibitory activity and improve solubility or other physicochemical properties. Clinical trials of PARP1 inhibitor were focused on cancer therapies and have achieved remarkable results.Export Options
About this article
Cite this article as:
Cao Mengda , Sun Xi , Zhou Yanjun, Huang Wen, Meng Ling *, Wei Ji-Fu *, Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review, Recent Patents on Anti-Cancer Drug Discovery 2017; 12 (3) . https://dx.doi.org/10.2174/1574892812666170508124932
DOI https://dx.doi.org/10.2174/1574892812666170508124932 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Coffee and Depression: A Short Review of Literature
Current Pharmaceutical Design Redox State in Atrial Fibrillation Pathogenesis and Relevant Therapeutic Approaches
Current Medicinal Chemistry The Quality of Life of Thalassemic Patients: The Role of Endocrine Defect Compensation
Endocrine, Metabolic & Immune Disorders - Drug Targets Mass Spectrometry-Based Metabolic Profiling
Current Metabolomics Editorial: (Persistent Elevation of Blood Pressure in Children and Adolescents is Associated with Arterial Hypertension and Premature Atherosclerosis in Adults. Is it Possible to Reverse this?)
Current Vascular Pharmacology Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Anthocyanins: Chemical Properties and Health Benefits: A Review
Current Nutrition & Food Science Probiotics as an Alternative Strategy for Prevention and Treatment of Human Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Proteomics and Cardiovascular Disease: An Update
Current Medicinal Chemistry Nutrigenetics of the Postprandial Lipoprotein Metabolism: Evidences From Human Intervention Studies
Current Vascular Pharmacology Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Current Genomics in Cardiovascular Medicine
Current Genomics Adenosine and Adenosine Receptors in the Pathomechanism and Treatment of Respiratory Diseases
Current Medicinal Chemistry Coumarine Analogues with Antimycobacterial and Immunomodulatory Activity
Current Bioactive Compounds The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part I: (Patho)-Physiology, Rationale and Perspective on Pulse Pressure Amplification
Current Pharmaceutical Design Pharmacophore-based Screening for Identification of Human Acyl-CoA Cholesterol Acyltransferase Inhibitors: An In-silico Study
Letters in Drug Design & Discovery Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design The Oxygen Therapy
Current Medicinal Chemistry Achieving Better Blood Pressure Control in High-Risk Patients with Type 2 Diabetes Using Combination Antihypertensive Therapy
Vascular Disease Prevention (Discontinued) Efficacy of Adjunctive Brexpiprazole in Patients with Major Depressive Disorder: A Clinical Overview
Current Psychiatry Reviews